Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : India Coffee House -- Ignore unavailable to you. Want to Upgrade?

To: Mohan Marette who wrote (3746)	2/18/1999 12:13:00 AM
From: Mohan Marette	Respond to of 12475

Ranbaxy, Cipla in strategic tie-up Wednesday 17, Feb. '99 Ranbaxy and Cipla, have entered into a strategic patnership to jointly market a select basket of drugs. The alliance will bring forth their strengths in the strongly emerging cardiovascular and perennial anti- infectives market. Subsequently the alliance shall expand to include other thereapeutic segments. As a first step, the tow molecules being jointly launched are Carvedilol, a new generation antipy pertensive and Cefpodoxime Proxetil, an advanced third generation oral cephalosporin. While Ranbaxy will market the anti- hypertensive under the brand name, Caslot and the oral cephalosporin under the brand name Cepodem, Cipla will market them under the brand names of Carloc and Cefoprox respectively. The brands will be marketed jointly by the Ranbaxy and Cipla field forces. Carvedilol has been developed by Cipla and Cefpodoxime by Ranbaxy and each will buy the bulk from the other. The alliance will enable both companies to pool their product development capabilities, product mix and marketing strengths. The companies feel the partnership will be a "win-win" situation when the product patent regime comes into effect. The partnership will enable both Ranbaxy and Cipla to aggresively leverage their marketing prowess, optimise production through economies of scale and exploit their distribution muscle. This is Cipla's first co-marketing arrangement. Ranbaxy has a similar alliance with Hoechst Marrion Roussel (HMR). (source:cmots)